Equine sarcoid therapy aims toward making jump to humans
A platform using viral vectors has demonstrated success in treating sarcoids in equines and is expected to begin to take the treatment to human patients. Blue Sky Immunotherapies GmbH Ltd., a biotech firm based in Austria, is the maker of the platform, called deINS.
The study, published in PLoS ONE, was conducted at the University of Veterinary Medicine Vienna’s oncology group. Based on study results, the skin tumors were significantly reduced and the bovine papillomavirus associated with sarcoids was destroyed. Standard treatments such as surgery and chemotherapy have mixed or inadequate results.
The study was conducted over 3 years with 29 horses. Results were: complete regression in 10 equines, significant and visible regression in 20 horses.
"The complete elimination of very aggressive and difficult-to-cure equine sarcoids is yet another important proof of the potential offered by our delNS platform. We are therefore confident that we will also be able to successfully heal and/or eliminate the cervical tumours of the women enrolled in the clinical trials currently underway,” said Thomas Muster, chief executive officer of BlueSky Immunotherapies
The deINS/E6E7 technology uses viral vectors to stimulate an immune response by provoking interferon and tumor antigen expression. The treatment also blocks immune suppression common with the tumors, according to the company.
Comments
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment